Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive intravenous tranexamic acid before total knee arthroplasty in rheumatoid arthritis
ChiCTR2000029720Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid in rheumatoid arthritis (RA) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: total blood loss, hidden blood loss and 1 more. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000029720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029720.